Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of “Hold” from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has received an average recommendation of “Hold” from the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $5.40.

A number of equities research analysts have weighed in on the stock. Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $8.00 to $2.00 in a research report on Thursday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday.

Fractyl Health Stock Down 5.4%

Shares of NASDAQ:GUTS opened at $0.47 on Friday. The business has a 50-day moving average price of $0.73 and a 200 day moving average price of $1.28. The company has a current ratio of 4.78, a quick ratio of 4.27 and a debt-to-equity ratio of 3.23. The company has a market capitalization of $75.07 million, a price-to-earnings ratio of -0.26 and a beta of 1.51. Fractyl Health has a 12-month low of $0.38 and a 12-month high of $3.03.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Tuesday, March 24th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.34. Sell-side analysts expect that Fractyl Health will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in Fractyl Health during the 2nd quarter worth about $31,000. FNY Investment Advisers LLC acquired a new position in Fractyl Health in the 3rd quarter valued at about $31,000. Jump Financial LLC acquired a new position in Fractyl Health in the 4th quarter valued at about $57,000. Scientech Research LLC acquired a new position in Fractyl Health in the 3rd quarter valued at about $49,000. Finally, Prelude Capital Management LLC purchased a new stake in Fractyl Health during the third quarter worth about $55,000.

More Fractyl Health News

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Q4 2025 results and earnings-call takeaways showed better-than-expected results and operational color that investors liked — management highlighted the quarter and outlook that helped drive upside reaction. Earnings Call Highlights
• Positive Sentiment: Analysts moved more bullish: HC Wainwright raised FY2029–FY2030 EPS estimates and reiterated a Buy with an $8 price target; Canaccord also reaffirmed a Buy and $8 PT — both signals can attract momentum buying given the large implied upside vs. the current price. Analyst Notes (MarketBeat) Canaccord Note
• Positive Sentiment: Shares jumped sharply in after-hours trading (reported ~21% move) on the combination of the results, call and analyst commentary — a clear short-term bullish reaction. After-hours Coverage
• Neutral Sentiment: The full Q4 2025 earnings call transcript is available for investors who want the exact management comments; use it to judge sustainability of the upbeat guidance and timing of any commercial/clinical milestones. Call Transcript
• Neutral Sentiment: Macro and micro risks remain: the consensus for the current fiscal year is still a material loss (analyst consensus ~-1.61 EPS), the stock is low-priced with thin liquidity and is trading below its 50- and 200-day averages — factors that can amplify volatility but not necessarily change the fundamental reaction to positive news.
• Negative Sentiment: The company disclosed a new regulation/compliance risk tied to global anti‑corruption and sanctions laws — this raises potential legal/compliance costs and execution risk that could weigh on valuation if it leads to investigations, fines, or limits on international activity. Compliance Risk Notice

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.